Antimicrobial therapy of Staphylococcus aureus bloodstream infection

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 15, 2007, Pages 2505-2518

  Tacconelli, Evelina ^a   Cataldo, Maria A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bloodstream infection; Daptomycin; Linezolid; Methicillin resistant Staphylococcus aureus; Methicillin susceptible Staphylococcus aureus; Quinupristin dalfopristin; Teicoplanin; Tigecycline; Vancomycin

Indexed keywords

7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; 7BETA [2 (5 AMINO 1,2,4 THIADIAZOL 3 YL) 2 ETHOXYIMINOACETAMIDO] 3 [(1 METHYLAMINOPROPYL 1H IMIDAZO[4,5 B]PYRIDINIUM 4 YL)METHYL] 3 CEPHEM 4 CARBOXYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CB 181963; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCLOXACILLIN; GENTAMICIN; LB 11058; LINEZOLID; NAFCILLIN; ORITAVANCIN; OXACILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WCK 771;

ABDOMINAL CRAMP; ABDOMINAL INFECTION; ABDOMINAL PAIN; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; APLASTIC ANEMIA; ARTHRALGIA; ASEPTIC MENINGITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL VIRULENCE; BILE DUCT DISEASE; BLOOD CLOTTING DISORDER; BLOOD DISEASE; BLOOD DYSCRASIA; BONE MARROW TOXICITY; BRONCHOSPASM; BULLOUS SKIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COLITIS; CONSTIPATION; CONTINUOUS INFUSION; CONVULSION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ELECTROLYTE DISTURBANCE; ENDOCARDITIS; EOSINOPHILIA; ERYTHEMA; ESOPHAGITIS; FLU LIKE SYNDROME; FLUSHING; GLOSSITIS; GOUT; HEARING LOSS; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEPATITIS; HOSPITAL INFECTION; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOPROTEINEMIA; HYPOTENSION; INFECTION RISK; INJECTION SITE ABSCESS; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INSOMNIA; INTERSTITIAL NEPHRITIS; JAUNDICE; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LACTIC ACIDOSIS; LETHARGY; LEUKOPENIA; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LUNG INFILTRATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MUSCLE SPASM; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OTOTOXICITY; PAIN; PANCREATITIS; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHLEBITIS; POSTOPERATIVE INFECTION; PRURITUS; PSEUDOMEMBRANOUS COLITIS; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SKIN EXFOLIATION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; STOMATITIS; SURGICAL INFECTION; TASTE DISORDER; THORAX PAIN; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THRUSH; TINNITUS; TOXIC EPIDERMAL NECROLYSIS; UREA BLOOD LEVEL; VENTILATOR ASSOCIATED PNEUMONIA; VERTIGO; VESTIBULAR DISORDER; VOMITING; WHEEZING; XEROSTOMIA;

ANTI-INFECTIVE AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 35648993084     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.15.2505     Document Type: Review

References (95)

1. WYLLIE DH, CROOK DW, PETO TE: Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire 1997-2003: cohort study. BMJ (2006) 333(7562):281.
2. STYERS D, SHEEHAN DJ, HOGAN P SAHM DF: Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. (2006) 5:2.
3. CUNHA BA: Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin. Microbiol. Infect. (2005) 11(Suppl. 4):33-42.
4. SCHENTAG JJ, HYATT JM, CARR JR et al.: Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium and the importance of antibiotic management and infection control. Clin. Infect. Dis. (1998) 26(5):1204-1214.
5. OLIVEIRA DC, TOMASZ A, DE LENCASTRE H: Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant Staphylococcus aureus. Lancet Infect. Dis. (2002) 2(3):180-189.
6. PACE JL, YANG G: Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. (2006) 71(7):968-980.
7. HIRAMATSU K, HANAKI H, INO T, YABUTA K, OGURI T, TENOVER FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. (1997) 40(1):135-136.
8. HIRAMATSU K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. (2001) 1:147-155.
9. CHANG S, SIEVERT DM, HAGEMAN JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. (2003) 348(14):1342-1347.
10. JENKINS SG: Trends associated with glycopeptides: heteroresistance, tolerance, and lack of detection. Clin. Updates Infect. Dis. (2006) 7(2):1-6.
11. LEUTHNER KD, CHEUNG CM, RYBAK MJ: Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (2006) 58(2):338-343.
12. BAL AM, GOULD IM: Antibiotic resistance in Staphylococcus aureus and its relevance in therapy. Expert Opin. Pharmacother. (2005) 6(13):2257-2269.
13. Clinical and Laboratory Standard Institute (CLSI): Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16. Wayne, PA: CLSI (2006).
14. TACCONELLI E, VENKATARAMAN L, DE GIROLAMI PC, DAGATA EM: Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains. J. Antimicrob. Chemotber. (2004) 53(3):474-479.
15. RUBINOVITCH B, PITTET D: Screening for methicillin-resistant Staphylococcus aureus in the endemic hospital: what have we learned? J. Hosp. Infect. (2001) 47(1):9-18.
16. COSGROVE SE, QI Y, KAYE KS, HARBARTH S, KARCHMER AW, CARMELI Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control. Hosp. Epidemiol. (2005) 26(2):166-174.
17. COSGROVE SE, SAKOULAS G, PERENCEVICH EN, SCHWABER MJ, KARCHMER AW, CARMELI Y: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. (2003) 36(1):53-59.
18. TACCONELLI E, POP-VICAS AE, D'AGATA EM: Increased mortality among elderly patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Hosp. Infect. (2006) 64(3):251-256.
19. GUILARDE AO, TURCHI MD, MARTELLI CM, PRIMO MG: Staphylococcus aureus bacteraemia: incidence, risk factors and predictors for death in a Brazilian teaching hospital. J. Hosp. Infect. (2006) 63(3):330-336.
20. KIM SH, PARK WB, LEE KD et al.: Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. (2004) 54(2):489-497.
21. LODISE TP, MCKINNON PS, SWIDERSKI L, RYBAK MJ: Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2003) 36(11):1418-1423.
22. GEMMELL CG, EDWARDS DI, FRAISE AP, GOULD FK, RIDGWAY GL, WARREN RE; ON BEHALF OF HE JOINT WORKING PARTY OF THE BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY: Hospital infection society and infection control nurses association: guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J. Antimicrob. Chemother. (2006) 57:589-608.
23. BERRINGTON A, GOULD FK: Use of antibiotic locks to treat colonized central venous catheters. J. Antimicrob. Chemother. (2001) 48(5):597-603.
24. MITCHELL DH, HOWDEN BP: Diagnosis and management of Staphylococcus aureus bacteraemia. Intern. Med. J. (2005) 35:S17-S24.
25. SANDE MA, SCHELD WM: Combination antibiotic therapy of bacterial endocarditis. Ann. Intern. Med. (1980) 92(3):390-395.
26. CHANG FI, PEACOCK JE Jr, MUSHER DM et al.: Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) (2003) 82:333-339.
27. GONZALEZ C, RUBIO M, ROMERO-VIVAS J, GONZALEZ M, PICAZO JJ: Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin. Infect. Dis. (1999) 29(5):1171-1177.
28. KHATIB R, JOHNSON LB, FAKIH MG et al.: Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand. J. Infect. Dis. (2006) 38(1):7-14.
29. TACCONELLI E, KARCHMER AW, YOKOE D, D'AGATA EM: Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule. Clin. Infect Dis. (2004) 39(7):964-970.
30. FURTADO GH, MENDES RE, PIGNATARI AC, WEY SB, MEDEIROS EA: Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients: an analysis of two case-control studies. Am. J. Infect. Control. (2006) 34(7):447-451.
31. Preventing the spread of vancomycin resistance - a report from the hospital infection control practices advisory committee prepared by the subcommittee on prevention and control of antimicrobial-resistant microorganisms in hospitals; comment period and public meeting - CDC. Notice. Fed. Regist. (1994) 59(94):25758-25763.
32. BADER MS: Staphylococcus aureus bacteremia in older adults: predictors of 7-day mortality and infection with a methicillin-resistant strain. Infect. Control Hosp. Epidemiol. (2006) 27(11):1219-1225.
33. OZTOPRAK N, CEVIK MA, AKINCI E et al.: Risk factors for ICU-acquired methicillin-resistant Staphylococcus aureus infections. Am. J. Infect. Control (2006) 34(1):1-5.
34. DREW RH, PERFECT JR, SRINATH L, KURKIMILIS E, DOWZICKY M, TALBOT GH: Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid emergency-use study group. J. Antimicrob. Chemother. (2000) 46(5):775-784.
35. SAKOULAS G, MOISE-BRODER PA, SCHENTAG J, FORREST A, MOELLERING RC Jr, ELIOPOULOS GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. (2004) 42(6):2398-2402.
36. MOISE-BRODER PA, SAKOULAS G, ELIOPOULOS GM, SCHENTAG JJ, FORREST A, MOELLERING RC Jr: Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. (2004) 38(12):1700-1705.
37. SCHWABER MJ, WRIGHT SB, CARMELI Y et al.: Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg. Infect. Dis. (2003) 9(6):657-664.
38. HOWDEN BP: Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern. Med. J. (2005) 35(Suppl. 2):S136-S140
39. IWAMOTO T, KAGAWA Y, KOJIMA M: Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm. Bull. (2003) 26(6):876-879.
40. WYSOCKI M, DELATOUR F, FAURISSON F et al.: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. (2001) 45(9):2460-2467.
41. CALAIN P KRAUSE KH, VAUDAUX P et al.: Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J. Infect. Dis. (1987) 155(2):187-191.
42. SATO M, CHIDA K, SUDA T et al.: Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J. Infect. Chemother. (2006) 12(4):185-189.
43. HARDING I, MACGOWAN AP, WHITE LO, DARLEY ES, REED V: Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J. Antimicrob. Chemother. (2000) 45(6):835-841.
44. WOOD MJ: The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother. (1996) 37(2):209-222.
45. GANG RK, SANYAL SC, MOKADDAS E, LARI AR: Rifampicin as an adjunct to vancomycin therapy in MRSA septicaemia in burns. Burns (1999) 25(7):640-644.
46. BURNIE J, MATTHEWS R, JIMAN-FATAMI A, GOTTARDELLO P, HODGETTS S, D'ARCY S: Analysis of 42 cases of septicemia caused by in epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin. Infect. Dis. (2000) 31(3):684-689.
47. LEVINE DP, FROMM BS, REDDY BR. Slow response to vancomycin or vancomycin plus rifampin in MRSA endocarditis. Ann. Intern. Med. (1991) 115:674-680.
48. SANDE MA, COURTNEY KB: Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J. Lab. Clin. Med. (1976) 88(1):118-124.
49. SHELBURNE SA, MUSHER DM, HULTEN K et al: In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob. Agents Chemother. (2004) 48(10):4016-4019.
50. BADDOUR LM, WILSON WR, BAYER AS et al.: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American heart association: endorsed by the infectious diseases society of America. Circulation (2005) 111(23):394-434.
51. ANDRADE-BAIOCCHI S, TOGNIM MC, BAIOCCHI OC, SADER HS: Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn. Microbiol. Infect. Dis. (2003) 45(2):149-145.
52. ELLIS MW, LEWIS JS II: Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis. (2005) 18(6):496-501.
53. MARKOWITZ N, QUINN EI, SARAVOLATZ LD: Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Int. Med. (1992) 117:390-398.
54. LEWIS JS II, JORGENSEN JH: Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin. Infect. Dis. (2005) 40(2):280-285.
55. PATERSON DL: Clinical experience with recently approved antibiotics. Curr. Opin. Pharmacol. (2006) 6:486-489.
56. ROSS JE, ANDEREGG TR, SADER HS FRITSCHE TR, JONES RN: Trends in linezolid susceptibility patterns in 2002: report from the worldwide zyvox annual appraisal of potency and spectrum program. Diagn. Microbiol. Infect. Dis. (2005) 52(1):53-58.
57. POTOSKI BA, ADAMS J, CLARKE L et al.: Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin. Infect. Dis. (2006) 43(2):165-171.
58. WUNDERINK RG, RELLO J, CAMMARATA SK, CROOS-DABRERA RV, KOLLEF MH: Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 124(5):1789-1797.
59. KOLLEFMH, RELLO J, CAMMARATA SK et al.: Clinical cure and survival in Gram-positive ventilator-associated pneumonia, retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med . (2004) 30:388-394.
60. AMERICAN THORACIC SOCIETY DOCUMENTS: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. (2005) 171:388-416.
61. SHORR AF, KUNKEL MJ, KOLLEF M: Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. (2005) 56(5):923-929.
62. BIRMINGHAM MC, RAYNER CR, MEAGHER AK, FLAVIN SM, BATTS DH, SCHENTAG JJ: Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. (2003) 36:159-168.
63. LEE SY, FAN HW, KUTI JL, NICOLAU DP: Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin. Pharmacother. (2006) 7(10):1381-1397.
64. RAND KH, HOUCK HJ: Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2004) 48(8):2871-2875.
65. MARTY FM, YEH WW, WENNERSTEN CB: Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. (2006) 44(2):595-597.
66. FOWLER VG Jr, BOUCHER HW, COREY GR et al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. (2006) 355(7):653-665.
67. SCHEETZ M, REDDY P, POSTELNICK M, FLAHERTY J: In vivo synergy of daptomycin plus a penicillin agent for MRSA? J. Antimicrob. Chemother. (2005) 55(3):398-399.
68. BLONDEAU JM, SANCHE SE: Quinupristin/dalfopristin. Expert Opin. Pharmacother. (2002) 3(9):1341-1364.
69. FUCHS PC, BARRY AL, BROWN SD: Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob. Agents Chemother. (2000) 44(10):2880-2882.
70. HERSHBERGER E, DONABEDIAN S, KONSTANTINOU K, ZERVOS MJ: Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin. Infect. Dis. (2004) 38(1):92-98.
71. TALBOT GH, BARRIERE S, CERWINKA S et al.: Efficacy of quinupristin-dalfopristin in the treatment of patients with positive blood cultures in global Phase III studies. Proceedings of the 20th International Congress of Chemotherapy (ICC). Sydney, Australia (29 June - 3 July 1997).
72. SGARABOTTO D, CUSINATO R, NARNE E et al.: Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand. J. Infect. Dis. (2002) 34(2):122-126.
73. SCOTTON PG, RIGOLI R, VAGLIA A: Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens. Infection (2002) 30(3):161-163.
74. SADER HS, JONES RN, STILWELL MG, DOWZICKY MJ, FRITSCHE TR: Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. (2005) 52(3):181-186.
75. HOBAN DJ, BOUCHILLON SK, JOHNSON BM, JOHNSON JL, DOWZICKY MJ: Tigecycline evaluation and surveillance trial (TEST Program) group: In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. (2005) 52(3):215-227.
76. MEAGHER AK, AMBROSE PG, GRASELA TH, ELLIS-GROSSE EJ: The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. (2005) 41(Suppl. 5):S333-S340.
77. MUNOZ-PRICE LS, LOLANS K, QUINN JP: Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J. Infect. Dis. (2006) 38(11-12):1081-1084.
78. LIN SW, CARVER PL, DEPESTEL DD: Dalbavancin: a new option for the treatment of gram-positive infections. Ann. Pharmacother. (2006) 40(3):449-460.
79. STREIT JM, FRITSCHE TR, SADER HS, JONES RN: Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. (2004) 48(2):137-143.
80. BOZDOGAN B, ESEL D, WHITENER C, BROWNE FA, APPELBAUM PC: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52(5):864-868.
81. RAAD I, DAROUICHE R, VAZQUEZ J et al.: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. (2005) 40:374-380.
82. LEFORT A, PAVIE J, GARRY L, CHAU F, FANTIN B: Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob. Agents Chemother. (2004) 48(3):1061-1064.
83. MERCIER RC, HOULIHAN HH, RYBAK MJ: Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob. Agents Chemother. (1997) 41:1307-1312.
84. DRAGHI DC, MOECK G, THORNSBERRY C, SAHM DF: Comparative in vitro potency of oritavancin, teicoplanin, and vancomycin against glycopeptide-susceptible and -resistant gram-positive organisms. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (27-30 September 2006).
85. LEFORT A, SALEH-MGHIR A, GARRY L, CARBON C, FANTIN B: Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob. Agents Chemother. (2000) 44:3017-3021.
86. BHAVNANI SM, PASSARELL JA, OWEN JS, LOUTIT JS, PORTER SB, AMBROSE PG: Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. (2006) 50(3):994-1000.
87. SHAW JP, SEROOGY J, KANIGA K et al.: Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. (2005) 49:195-201.
88. BARCIA-MACAY M, LEMAIRE S, MINGEOT-LECLERCQ MP, TULKENS PM, VAN BAMBEKE F: Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (2006) 58(6):1177-1184.
89. STRYJEWSKI ME, CHU VH, O'RIORDAN WD et al.: Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. (2006) 50(3):862-867.
90. BOGDANOVICH T, EDNIE LM, SHAPIRO S, APPELBAUM PC: Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. (2005) 49(10):4210-4219.
91. DENIS O, DEPLANO A, NONHOFF C et al.: In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob. Agents Chemother. (2006) 50(8):2680-2685.
92. ENTENZA JM, HOHL P, HEINZE-KRAUSS I, GLAUSER MP, MOREILLON P: BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. (2002) 46(1):171-177.
93. DONOWITZ GR, MANDELL GL: β-Lactam antibiotics. N. Engl. J. Med. (1988) 318(7):419-426.
94. KOEK GH, STRICKER BH, BLOK AP, SCHALM SW, DESMET VJ: Flucloxacillin-associated hepatic injury. Liver (1994) 14(5):225-229.
95. SENNEVILLE E, LEGOUT L, VALETTE M et al.: Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J. Antimicrob. Chemother. (2004) 54(4):798-802.